Cargando…
BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition
BACKGROUND: Polyomavirus BK nephropathy (PyVAN) remains an important cause of early graft dysfunction and graft loss in kidney transplantation. METHODS: In this retrospective, single centre cohort study we studied the incidence and outcome of BK viral infection in 352 patients transplanted in 2008–2...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850699/ https://www.ncbi.nlm.nih.gov/pubmed/24088187 http://dx.doi.org/10.1186/1471-2369-14-207 |
_version_ | 1782294146288975872 |
---|---|
author | Jacobi, Johannes Prignitz, Antonina Büttner, Maike Korn, Klaus Weidemann, Alexander Hilgers, Karl F Heller, Katharina Velden, Joachim Knöll, Antje Wullich, Bernd May, Christoph Eckardt, Kai-Uwe Amann, Kerstin U |
author_facet | Jacobi, Johannes Prignitz, Antonina Büttner, Maike Korn, Klaus Weidemann, Alexander Hilgers, Karl F Heller, Katharina Velden, Joachim Knöll, Antje Wullich, Bernd May, Christoph Eckardt, Kai-Uwe Amann, Kerstin U |
author_sort | Jacobi, Johannes |
collection | PubMed |
description | BACKGROUND: Polyomavirus BK nephropathy (PyVAN) remains an important cause of early graft dysfunction and graft loss in kidney transplantation. METHODS: In this retrospective, single centre cohort study we studied the incidence and outcome of BK viral infection in 352 patients transplanted in 2008–2011. RESULTS: During follow-up viral replication was detected in 48 patients (13.6%); 22 patients (6.2%) had biopsy proven PyVAN. In multivariate logistic regression analyses risk factors for BK-viremia were lack of enrolment into randomized controlled trials (RCTs), biopsy proven acute rejections, cytomegaly virus (CMV) serostatus of both donor and recipient and previous transplantation. In patients without PyVAN reduction or switch of immunosuppression was associated with rapid viral clearance and stable graft function. In contrast, in most patients with PyVAN graft function deteriorated and 5 patients prematurely lost their allograft. Switch of immunosuppression to a low dose cyclosporine plus mTOR inhibitor based regimen in patients with PyVAN was safe, well tolerated and tended to be associated with a better short-term outcome in terms of graft function compared to reduction of existing immunosuppression alone. CONCLUSIONS: With the lack of licensed anti-polyoma viral drugs reduction or conversion of immunosuppression remains the mainstay of therapy in patients with PyVAN. The combination of low dose cyclosporine plus mTOR inhibition appears to be safe and warrants further investigation. |
format | Online Article Text |
id | pubmed-3850699 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-38506992013-12-05 BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition Jacobi, Johannes Prignitz, Antonina Büttner, Maike Korn, Klaus Weidemann, Alexander Hilgers, Karl F Heller, Katharina Velden, Joachim Knöll, Antje Wullich, Bernd May, Christoph Eckardt, Kai-Uwe Amann, Kerstin U BMC Nephrol Research Article BACKGROUND: Polyomavirus BK nephropathy (PyVAN) remains an important cause of early graft dysfunction and graft loss in kidney transplantation. METHODS: In this retrospective, single centre cohort study we studied the incidence and outcome of BK viral infection in 352 patients transplanted in 2008–2011. RESULTS: During follow-up viral replication was detected in 48 patients (13.6%); 22 patients (6.2%) had biopsy proven PyVAN. In multivariate logistic regression analyses risk factors for BK-viremia were lack of enrolment into randomized controlled trials (RCTs), biopsy proven acute rejections, cytomegaly virus (CMV) serostatus of both donor and recipient and previous transplantation. In patients without PyVAN reduction or switch of immunosuppression was associated with rapid viral clearance and stable graft function. In contrast, in most patients with PyVAN graft function deteriorated and 5 patients prematurely lost their allograft. Switch of immunosuppression to a low dose cyclosporine plus mTOR inhibitor based regimen in patients with PyVAN was safe, well tolerated and tended to be associated with a better short-term outcome in terms of graft function compared to reduction of existing immunosuppression alone. CONCLUSIONS: With the lack of licensed anti-polyoma viral drugs reduction or conversion of immunosuppression remains the mainstay of therapy in patients with PyVAN. The combination of low dose cyclosporine plus mTOR inhibition appears to be safe and warrants further investigation. BioMed Central 2013-10-02 /pmc/articles/PMC3850699/ /pubmed/24088187 http://dx.doi.org/10.1186/1471-2369-14-207 Text en Copyright © 2013 Jacobi et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Jacobi, Johannes Prignitz, Antonina Büttner, Maike Korn, Klaus Weidemann, Alexander Hilgers, Karl F Heller, Katharina Velden, Joachim Knöll, Antje Wullich, Bernd May, Christoph Eckardt, Kai-Uwe Amann, Kerstin U BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition |
title | BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition |
title_full | BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition |
title_fullStr | BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition |
title_full_unstemmed | BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition |
title_short | BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition |
title_sort | bk viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mtor inhibition |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850699/ https://www.ncbi.nlm.nih.gov/pubmed/24088187 http://dx.doi.org/10.1186/1471-2369-14-207 |
work_keys_str_mv | AT jacobijohannes bkviremiaandpolyomavirusnephropathyin352kidneytransplantsriskfactorsandpotentialroleofmtorinhibition AT prignitzantonina bkviremiaandpolyomavirusnephropathyin352kidneytransplantsriskfactorsandpotentialroleofmtorinhibition AT buttnermaike bkviremiaandpolyomavirusnephropathyin352kidneytransplantsriskfactorsandpotentialroleofmtorinhibition AT kornklaus bkviremiaandpolyomavirusnephropathyin352kidneytransplantsriskfactorsandpotentialroleofmtorinhibition AT weidemannalexander bkviremiaandpolyomavirusnephropathyin352kidneytransplantsriskfactorsandpotentialroleofmtorinhibition AT hilgerskarlf bkviremiaandpolyomavirusnephropathyin352kidneytransplantsriskfactorsandpotentialroleofmtorinhibition AT hellerkatharina bkviremiaandpolyomavirusnephropathyin352kidneytransplantsriskfactorsandpotentialroleofmtorinhibition AT veldenjoachim bkviremiaandpolyomavirusnephropathyin352kidneytransplantsriskfactorsandpotentialroleofmtorinhibition AT knollantje bkviremiaandpolyomavirusnephropathyin352kidneytransplantsriskfactorsandpotentialroleofmtorinhibition AT wullichbernd bkviremiaandpolyomavirusnephropathyin352kidneytransplantsriskfactorsandpotentialroleofmtorinhibition AT maychristoph bkviremiaandpolyomavirusnephropathyin352kidneytransplantsriskfactorsandpotentialroleofmtorinhibition AT eckardtkaiuwe bkviremiaandpolyomavirusnephropathyin352kidneytransplantsriskfactorsandpotentialroleofmtorinhibition AT amannkerstinu bkviremiaandpolyomavirusnephropathyin352kidneytransplantsriskfactorsandpotentialroleofmtorinhibition |